If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
248
results.
Updated on
19/04/2026 [07:16:00]
Results 50 to 75 of 248
Absstract of: US20260086086A1
0000 Embodiments may include a rapid test device that provide rapid detection of substances, including those involved in pathogen infection, for example, using Microscale Affinity Chromatography (MAC), indirect ELISA, and optical molecular sensing technology. For example, in an embodiment, an apparatus may comprise a loading bay disposed on the apparatus to receive a cartridge, a door disposed on the apparatus to cover the loading bay, a plurality of prongs disposed on an interior of the door to provide actuation force to dispense blister reservoirs disposed on the cartridge when the door is closed, and a device disposed relative to the cartridge to move at least a portion of contents of the cartridge among chambers of the cartridge.
Absstract of: US20260086063A1
0000 Circulatory failure generates hypoxia and leads to accumulation of reductive species in tissue and circulatory failure monitoring tools are needed but rare. Cardiopulmonary bypass (CPB) is known to promote brief circulatory failure during its initiation. In the present study, the Inventors demonstrate a correlation between whole blood redox potential and circulatory failure during (CPB). They made a prospective study with 17 patients eligible for cardiac surgery with cardiopulmonary bypass. They demonstrated a frank reduction of the whole blood redox potential during circulatory failure during the initiation of CPB. They also demonstrated that they were able to classify patients in 3 groups, one of them presenting an unfavorable post-operative outcome. Accordingly, the present invention relates to a method of diagnosing acute circulatory failure in a patient comprising determining the level of redox potential in a sample obtained from said patient, wherein the level of redox potential indicates whether the patient suffers or not from an acute circulatory failure.
Absstract of: WO2026064655A1
Provided are nucleic acids encoding voltage indicator polypeptides. In some instances, the voltage indicator polypeptide comprises a voltage-sensing domain (VSD) comprising four transmembrane segments, and a circularly permuted fluorescent protein inserted into an extracellular loop between the third transmembrane segment (S3) and the fourth transmembrane segment (S4) of the VSD. The voltage indicator polypeptide may comprise one or more amino acid substitutions and/or deletions, non-limiting examples of which include one or more substitutions at I412, F413 and/or Q414, wherein numbering of positions is according to SEQ ID NO: 1. Cells comprising the nucleic acids are also provided. In some embodiments, the cells are neurons that express the voltage indicator polypeptide on the plasma membrane of the neuron in a pan-membrane or targeted manner. Methods of recording the electrical activity of neurons are also provided, as are methods of assessing an effect of an agent on the electrical activity of neurons.
Absstract of: CN121152975A
The present invention relates to the use of biomarkers for measuring the efficacy or effectiveness of a treatment for neurodegenerative diseases, in particular Alzheimer's disease.
Absstract of: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Absstract of: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Absstract of: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Absstract of: CN121721289A
本发明属于分子生物学领域，具体地，涉及一种空间蛋白质组学分析方法，更具体地，涉及一种同时进行细胞类型成像和原位蛋白质组学分析的空间蛋白质组学分析方法。使用本发明的方法能够在同一组织切片上同时进行细胞类型成像和原位蛋白质组学分析，减小潜在的偏差，使得分析结果更为准确。
Absstract of: CN121721265A
本公开涉及生物医学传感领域，具体涉及一种基于人工智能算法的单分子计数免疫分析系统，用于解决现有技术中在痕量蛋白检测和定量分析方面的灵敏度不足、信噪比不足、定量精度受限和数据处理效率低等问题。本公开技术方案通过明场和暗场双模式成像技术，针对基于利用离散载体及微纳荧光材料进行免疫分析的体系，结合图像处理算法和深度学习模型，提供高灵敏度、高精度、高信噪比的单分子免疫物质检测。
Absstract of: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Absstract of: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Absstract of: WO2024263939A1
The present disclosure relates method of identifying a compound targeting a first protein and a second protein, wherein the first protein and/or the second protein are associated with a disease or disorder.
Absstract of: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Absstract of: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Absstract of: WO2026057545A1
The present disclosure relates to novel antibodies and antigen-binding fragments thereof that specifically bind to human stimulator of interferon genes (STING), and uses of these antibodies and antigen-binding fragments thereof for treating diseases and disorders (e.g., inflammatory diseases or an autoimmune diseases).
Absstract of: US20260079168A1
0000 The technology relates in part to antibodies or antigen-binding fragments thereof that bind Tau phosphorylated at threonine 217 (Tau phospho (Thr217)) or a portion thereof, as well as methods, systems and kits for detection of Tau phospho (Thr217). In certain aspects, the technology relates to antibodies or antigen binding fragments thereof for use in determining levels of Tau phospho (Thr217) in a sample containing or suspected of containing Tau phospho (Thr217). In some aspects, the technology relates to antibodies or antigen-binding fragments thereof for use in diagnosing or treating an individual with or suspected of having a disease or disorder associated with Tau phospho (Thr217).
Absstract of: WO2026055750A1
The present disclosure relates to the field of oligonucleotides. More particularly, the present disclosure relates to antisense oligonucleotides for the specific binding and inhibition of translation of Chitinase (CHIT1) encoding mRNA. Additionally, this disclosure relates to methods of using such oligonucleotides in preventing or treating diseases, disorders or conditions associated with CHIT1, such as neurodegenerative or neuroinflammatory diseases, disorders or conditions like ALS.
Absstract of: WO2026060258A1
Disclosed herein is the use of gut microbiome (GM) as a therapeutic target for Parkinson's Disease (PD). Metagenomic biomarkers are identified that can stratify patients based on their dysbiotic features. Therefore, also disclosed is a companion diagnostic designed to identify patients that can be treated with an inhibitor of microbially induced amyloid.
Absstract of: WO2026060271A1
Methods for identifying chronic hydrocephalus include assaying for an amount in a biological sample of one or more biomarkers selected from pyruvate dehydrogenase lipoamide kinase isozyme 4 (PDK4), phosphofructokinase-muscle (PFKM), low density lipoprotein receptor adaptor protein 1 (LDLRAP1), glucagon-like peptide-1 receptor (GLP-1R), hemoglobin subunit alpha 1 (HBA1), hemoglobin subunit alpha 2 (HBA2), heme oxygenase 1 (HMOX1), and combinations thereof. Methods for screening for a compound useful for treating chronic hydrocephalus are also provided and include contacting a cell with an effective amount of a test compound, and then detecting an expression or activity level of one or more of the biomarkers.
Absstract of: WO2026060193A1
Binding reagents for tau protein variants, including antibodies that bind to tau protein, and uses thereof are disclosed. The uses include determining if a patient has or is at risk of developing a tauopathy, and treating a patient having a tauopathy.
Absstract of: US20260079151A1
0000 A 3D immunomechanical model of myeloid cells for use in basic research and drug screening that allows for observation of the myeloid-mechanical interaction in the context of a range of different mechanical and immunological-related diseases. The model is also suitable for applications such as high-throughput drug screening and experiments in a microgravity environment such as low earth orbit.
Absstract of: US20260079153A1
0000 Methods for generating mature neurons differentiated from pluripotent stem cells, such as to facilitate the study of late-onset neurodegenerative disease, are disclosed. The methods include overexpressing the splicing factor muscleblind like splicing regulator 2 (Mbnl2) in cortical neurons. In some aspects, the method further comprises overexpressing RNA binding fox-1 homolog 1 (Rbfox1) and/or reducing expression of polypyrimidine tract binding proteins PTBP1/2. The methods also include accelerated derivation of mature neuron and generation of a tau pathology model. Also disclosed are constructs and compositions for accelerated derivation of mature neuron and/or generation of a tau pathology model.
Absstract of: US20260079158A1
Disclosed are assays, reagents, and methods for ultrasensitive detection of target molecules. The assay comprises fusion proteins including binding moieties, such as antibodies, nanobodies (VHH/VNAR), or aptamers, linked to nonfunctional fragments of a protein. In the presence of a target molecule, the binding moieties recognize distinct target regions and bring the protein fragments into close proximity, reconstituting a functional protein that generates a detectable signal. Linkers connecting the fusion components may be flexible peptides or polypeptides that spontaneously form dimers, trimers, or tetramers, thereby providing multivalent fusion proteins with enhanced sensitivity. The reconstituted protein may produce luminescent, fluorescent, colorimetric, or spectroscopic signals detectable by microplate readers, handheld luminometers, or lateral flow devices. The invention encompasses solid-phase, homogeneous, and lateral flow assay formats for detecting viruses, bacteria, proteins, peptides, or small molecules, including GLRaV-3, SARS-CoV-2, PSA, and E. coli. The disclosed assays exhibit improved specificity, reduced background, and enhanced signal-to-noise ratios.
Absstract of: WO2026059929A1
Methods and systems disclosed herein can improve the quality of blood-derived samples (e.g., whole blood, serum, or plasma sample). In an aspect, the present disclosure provides a method of evaluating a plasma sample quality, comprising collecting a blood sample from a subject; processing the blood sample to separate a plasma sample from other blood components; quantitatively measuring amounts of one or more analytes present in the plasma sample, wherein the one or more analytes comprise hemoglobin, potassium (K), lactate, or formaldehyde (CH2O); and evaluating the quality of the plasma sample based at least in part on the measured amounts, wherein the measured amounts are indicative of the plasma sample quality. In another aspect, the present disclosure provides a method of adjusting for preanalytical bias utilizing a linear regression model to improve a signal to noise ratio, thereby potentially enhancing the performance of a classification model.
Nº publicación: AU2026201500A1 19/03/2026
Applicant:
BANNER HEALTH
THE GENERAL HOSPITAL CORP
THE SCHEPENS EYE RESEARCH INSTITUTE INC
Banner Health,
The General Hospital Corporation,
The Schepens Eye Research Institute, Inc
Absstract of: AU2026201500A1
Abstract Methods and compositions for preventing or treating cognitive decline associated with dementia and/or mild cognitive impairment and/or neurodegeneration using antibodies, peptides, fusion proteins, or genome editing systems that modulate HSPG/heparin binding affinities of ApoE.
BOPI
Electronic site
